Tumor necrosis factor inhibitors are an effective treatment for psoriatic arthritis, but no single agent is effective in all patients. Novel therapies that target other cytokines have now been tested, with encouraging results.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gladman, D. D. Psoriatic arthritis. Dermatol. Ther. 22, 40–55 (2009).
Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).
Soriano, E. R. & McHugh, N. J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J. Rheumatol. 33, 1422–1430 (2006).
Ribbens, C. et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur. Cytokine Netw. 11, 669–676 (2000).
Hueber, A. J. & McInnes, I. B. Immune regulation in psoriasis and psoriatic arthritis—recent developments. Immunol. Lett. 114, 59–65 (2007).
Ravindran, V., Scott, D. L. & Choy, E. H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum. Dis. 67, 855–859 (2008).
Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 41, 199–204 (2009).
Hüffmeier, U. et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 129, 355–358 (2009).
Rahman, P. et al. Association of interleukin-23R variants with psoriatic arthritis. J. Rheumatol. 36, 137–140 (2009).
Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
The author declares no competing financial interests.
About this article
Cite this article
Gladman, D. Targeted therapy for psoriatic arthritis. Nat Rev Rheumatol 5, 241–242 (2009). https://doi.org/10.1038/nrrheum.2009.76
Expert Review of Clinical Pharmacology (2014)
Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
Clinical Chemistry and Laboratory Medicine (2013)
Current Rheumatology Reports (2011)
Expert Opinion on Investigational Drugs (2010)